Revvity Inc delivered a solid Q3 2025 with revenue of $698.9 million, down 4.2% year over year and 3.0% quarter over quarter. The gross margin expanded modestly to 53.6%, reflecting favorable product mix and ongoing efficiency initiatives, while operating margin stood at 11.7% and net margin at 6.7%. Earnings per share were $0.40, supported by an EBITDA of $180.5 million and a robust depreciation and amortization level of $102.1 million. The company continues to generate meaningful operating cash flow per share (~$1.18) and free cash flow per share (~$1.02), underpinning a payout ratio of 17.4% and a cash-rich balance sheet with a cash per share of $7.91. Demand drivers remain anchored in two pillars: Discovery & Analytical Solutions and Diagnostics, with the Diagnostics segment positioned to benefit from growth in genomic workflows, early disease detection, and translational research. Near-term headwinds include a modest revenue pullback in a volatile macro environment and ongoing R&D intensity to sustain innovation pipelines. The absence of formal forward-looking guidance in the provided materials calls for close monitoring of product launches, clinical adoption rates, and capital allocation effectiveness going into 2026.